Search Results
You are looking at 1 - 8 of 8 items for
- Author: S. C. van Buul-Offers x
- Refine by access: All content x
Search for other papers by J A Koedam in
Google Scholar
PubMed
Search for other papers by C M Hoogerbrugge in
Google Scholar
PubMed
Search for other papers by S C van Buul-Offers in
Google Scholar
PubMed
Search for other papers by J L Van den Brande in
Google Scholar
PubMed
Abstract
The availability and activity of insulin-like growth factors (IGF-I and IGF-II) are largely determined by a group of IGF-binding proteins (IGFBPs). We have developed a new assay to characterize the interaction between the IGFs and IGFBP-3. In this assay, recombinant IGFBP-3 (5 ng) was immobilized on plastic microtitre wells, after which radiolabelled IGF-I or -II was allowed to bind. The assay is highly specific, since neither IGF bound to control wells blocked with albumin. By constructing both saturation and competition binding curves, equivalence of binding between the radiolabelled and native IGF ligands could be demonstrated. From these curves, reliable specific activities of the tracers were calculated. Scatchard plots of both types of data produced identical results for dissociation constants and number of binding sites. The affinity of IGF-II was twice as high as the affinity of IGF-I (dissociation constants of 44 and 102 pm respectively).
The assay was used to show that polyclonal anti-IGFBP-3 antibodies could block binding of IGF. Alkylating agents and NaCl were without effect, but chaotropic salts such as CaCl2 and NaSCN decreased IGF binding to IGFBP-3. IGFBP-1 and IGFBP-3, but not an N-terminal fragment of IGFBP-3, could effectively block binding of both IGF-I and IGF-II to the solid-phase IGFBP-3. Increasing concentrations of heparin had little or no effect on IGF-I binding, but strongly inhibited IGF-II binding. This was shown to be a consequence of a decrease in both the affinity and the number of binding sites. Possibly, the interaction of IGFBP-3 with heparin or heparin-like structures in vivo can lead to the selective release of IGF-II from this binding protein. Our results with heparin also suggest that the binding sites on IGFBP-3 for IGF-I and IGF-II are not completely identical.
This assay can be applied to the study of various aspects of the interaction between the IGFs and IGFBP-3, such as the effects of interfering substances and structure–function relationships of both moieties of the complex.
Journal of Endocrinology (1997) 153, 87–97
Search for other papers by S C van Buul-Offers in
Google Scholar
PubMed
Search for other papers by R J Bloemen in
Google Scholar
PubMed
Search for other papers by M G Reijnen-Gresnigt in
Google Scholar
PubMed
Search for other papers by H A van Leiden in
Google Scholar
PubMed
Search for other papers by C M Hoogerbrugge in
Google Scholar
PubMed
Search for other papers by J L Van den Brande in
Google Scholar
PubMed
Abstract
The ontogeny of serum insulin-like growth factors (IGFs)-I and -II and their binding proteins (IGFBPs) was studied in normal and dwarf Snell mice. IGF-I concentrations in serum of normal mice increased between 4 and 8 weeks of age; dwarf mice had very low serum IGF-I levels. In both normals and dwarfs, serum IGF-II levels were highest soon after birth and dropped steadily thereafter. Western ligand blots of serum IGFBPs with 125I-IGF-II as tracer revealed the expected bands 41·5, 38·5, 30–32 and 24 kDa. In normal mice the IGFBP-3 doublet was already detectable at 2 weeks of age, and its intensity increased with age. In dwarf mice the IGFBP-3 doublet was hardly detectable.
The changes of IGFs and their IGFBPs were studied in sera of dwarf mice after treatment with growth hormone (GH) and/or thyroxine (T4) for 4 weeks. In spite of a comparable growth response obtained using these hormones, serum IGF-I was increased only by GH treatment; a small but significant decrease of serum IGF-II was obtained following GH or T4 treatment. An increase of the IGFBP-3 doublet was only obtained with GH; T4 and GH+T4 had no effect. The rise of IGFBP-3 after GH treatment was accompanied by the formation of the IGFBP 150 kDa complex, as measured by neutral gel chromatography. The size distribution of 125 I-IGF-II was restored to normal, while with 125I-IGF-I only a small peak at 150 kDa was observed. Elution profiles of sera after treatment with T4 or GH+T4 were identical to those of dwarf controls.
The presence of the IGFBPs was investigated in media conditioned by liver and lung explants of normal and dwarf animals. In culture media of liver explants from normal mice, bands at 30–32 and 24 kDa predominated; the intensity of the IGFBP-3 doublet was relatively low. In dwarfs the 30–32 kDa predominated. In culture media of the lung from normal mice the IGFBP-3 doublet and the 24 kDa band were clearly visible; in dwarf mice IGFBPs could not be detected. We were unable to identify the 150 kDa IGFBP-complex in this medium using the size distribution of 125I-IGFs on neutral gel chromatography after incubation with the conditioned media. This was in contrast to data obtained with normal serum.
Our data suggest that serum IGFBP-3 and IGF-I are regulated by GH and not by T4. In dwarf Snell mice, serum IGF-II is down regulated by GH as well as T4. The 150 kDa IGFBP complex is absent in dwarfs and, when induced by GH, seems to have a high affinity for IGF-II.
Journal of Endocrinology (1994) 143, 191–198
Search for other papers by M.C. Slootweg in
Google Scholar
PubMed
Search for other papers by S.C. van Buul-Offers in
Google Scholar
PubMed
Search for other papers by M.P.M. Herrmann-Erlee in
Google Scholar
PubMed
Search for other papers by J.M. van der Meer in
Google Scholar
PubMed
Search for other papers by S.A. Duursma in
Google Scholar
PubMed
ABSTRACT
More evidence has recently been obtained indicating that growth hormone (GH) has a direct effect on bone. However, it is not clear which cell type reacts to the hormone. The present study used osteoblast-like cells derived from sequentially digested fetal mouse calvaria. Separately cultured tractions resulted in populations enriched in cells with a more or a less differentiated phenotype. The results showed that GH acts on the cells released last, i.e. those with more characteristics of the osteoblast. In these cells, GH induced strong mitogenic activity. Prolactin was not active.
Search for other papers by M. C. Slootweg in
Google Scholar
PubMed
Search for other papers by C. M. Hoogerbrugge in
Google Scholar
PubMed
Search for other papers by T. L. de Poorter in
Google Scholar
PubMed
Search for other papers by S. A. Duursma in
Google Scholar
PubMed
Search for other papers by S. C. van Buul-Offers in
Google Scholar
PubMed
ABSTRACT
Specific binding to and proliferative actions of insulinlike growth factors-I and -II (IGF-I and -II) on fetal mouse osteoblasts were tested. Membranes of mouse osteoblasts were shown by binding competition studies to possess specific binding sites for IGF-I and IGF-II. When IGF-I was used as a tracer, half-maximal displacement was obtained with 1·11 μg IGF-I/1 and with 14 μg IGF-II/1. Displacement of 125I-labelled IGF-I was accomplished with 2·33 μg IGF-II/1 and with 55 μg IGF-I/1. Affinity cross-linking showed bands of 130 kDa 125I-labelled IGF-I and 260 kDa 125I-labelled IGF-II under reducing conditions, further indicating the presence of classical type-I and -II receptor sites on mouse osteoblasts. Mitogenic effects of IGFs were weak; a combination with epidermal growth factor or fibroblast growth factor showed strong synergistic action however. The possibility of autocrine/paracrine actions of IGFs is discussed.
Journal of Endocrinology (1990) 125, 271-277
Search for other papers by M. C. Slootweg in
Google Scholar
PubMed
Search for other papers by S. C. van Buul-Offers in
Google Scholar
PubMed
Search for other papers by C. M. Hoogerbrugge in
Google Scholar
PubMed
Search for other papers by M. P. M. Herrmann-Erlee in
Google Scholar
PubMed
Search for other papers by A. J. M. van den Eijnden-van Raaij in
Google Scholar
PubMed
Search for other papers by S. A. Duursma in
Google Scholar
PubMed
Search for other papers by E. J. J. van Zoelen in
Google Scholar
PubMed
ABSTRACT
Bone matrix contains a variety of growth factors, but little is known of osteoblastic production of such materials. The present study assesses growth factor activity, chromatographed on acidic Bio-Gel P-100, secreted into conditioned media of primary cultures of fetal mouse calvaria. The cultures produced insulin-like growth factor-I (IGF-I), determined by radioimmuno-assay of molecular weights 20 and 10 kDa. IGF-II, determined by radioreceptor assay, was present at 20–29 and 7 kDa. The IGF peaks at 20, 10 and 7 kDa were all mitogenic in MCF-7 cells. Proteins of several different molecular weights were also present that specifically bound IGF-I and IGF-II. Transforming growth factor-β (TGF-β), assayed in a system for inhibition of growth, was also produced. Both activated and latent forms were present, and part of the TGF-β was TGF-β2. The absence of mitogenic activity in the bmolecular range of platelet-derived growth factor, assayed in 3T3 fibroblasts, makes it unlikely that mouse osteoblasts produce this growth factor.
Journal of Endocrinology (1990) 124, 301–309
Search for other papers by J. Jansen in
Google Scholar
PubMed
Search for other papers by S. C. van Buul-Offers in
Google Scholar
PubMed
Search for other papers by C. M. Hoogerbrugge in
Google Scholar
PubMed
Search for other papers by T. L. de Poorter in
Google Scholar
PubMed
Search for other papers by M. T. Corvol in
Google Scholar
PubMed
Search for other papers by J. L. Van den Brande in
Google Scholar
PubMed
ABSTRACT
The interaction of insulin-like growth factor (IGF)-I and IGF-II with specific type-I and -II receptor sites on rabbit articular chondrocyte membranes was studied. With labelled IGF-I as tracer, half-maximal displacement of the label was obtained with 1·4 ng IGF-I/ml and 22 ng IGF-II/ml. Using IGF-II as labelled peptide, 16 ng unlabelled IGF-II/ml and 200 ng IGF-I/ml were needed to inhibit the binding by 50%. Covalent cross-linking experiments revealed the presence of typical type-I (M r 130 000 under reducing conditions) and type-II (M r 260 000) receptor sites. In addition, with 125I-labelled IGF-II a very intense labelled band appeared at M r > 300 000. This band was not found in mouse liver membranes and human placental membranes.
Journal of Endocrinology (1989) 120, 245–249
Search for other papers by L Op De Beeck in
Google Scholar
PubMed
Search for other papers by J E A Verlooy in
Google Scholar
PubMed
Search for other papers by S C Van Buul-Offers in
Google Scholar
PubMed
Search for other papers by M V L Du Caju in
Google Scholar
PubMed
Abstract
A novel procedure for the detection of IGF binding capacity of IGFBPs on Western ligand blots (WLB) was developed using biotinylated IGFs as probes. The biotinylated IGF-IGFBP complexes were visualized by streptavidin-horseradish peroxidase and enhanced chemiluminescence (ECL). The procedure was found to be faster and more efficient than the conventional method with iodinated IGFs. In normal human serum a predominant doublet at 38-42 kDa and five smaller bands at 35, 34, 30, 28 and 24 kDa were detected by both methods, whereas two additional bands at 26 and 16 kDa became visible with the ECL method. In pregnancy serum only one single faint band at 30 kDa could be detected by the iodinated method. In contrast, the ECL method revealed five other bands at 42, 34, 28, 26 and 16 kDa. Besides the 38-42 kDa doublet, the 30 and 16 kDa bands reacted strongly with anti-IGFBP-3 antibodies in Western immunoblotting (WIB) and therefore were related to IGFBP-3 fragments. The technical advantages of this ECL method include an extremely short exposure time to the radiographic film and a long stability of the probe. In addition, the ECL method is a non-radioactive method, making radioprotection and radioactive waste removal unnecessary.
Search for other papers by S C van Buul-Offers in
Google Scholar
PubMed
Search for other papers by K de Haan in
Google Scholar
PubMed
Search for other papers by M G Reijnen-Gresnigt in
Google Scholar
PubMed
Search for other papers by D Meinsma in
Google Scholar
PubMed
Search for other papers by M Jansen in
Google Scholar
PubMed
Search for other papers by S L Oei in
Google Scholar
PubMed
Search for other papers by E J Bonte in
Google Scholar
PubMed
Search for other papers by J S Sussenbach in
Google Scholar
PubMed
Search for other papers by J L Van den Brande in
Google Scholar
PubMed
Abstract
In order to determine the effects of IGF-II overexpression on growth of mice, transgenic mice were produced carrying one of three different H-2Kb human IGF-II minigenes in which different non-coding exons (exon 5, truncated exon 5 or exon 6) preceded the coding exons 7, 8 and 9. These were spaced by truncated introns and for proper polyadenylation an SV40 polyadenylation signal was incorporated. The highest levels of IGF-II minigene mRNA expression were found in lines containing the truncated exon 5 construct (II5′). Those containing exon 6 (II6) had less expression and 5 constructs (II5) gave only moderate levels of mRNA expression. In general mRNA expression was highest in thymus and spleen, low in liver and kidney and absent in the brain. In addition, one 115' line showed expression in the brain. Serum IGF-II levels at 8 weeks of age were increased 7- to 8-fold in homozygous transgenic lines with construct II5′ without brain expression and 2- to 3-fold in the one that showed expression in the brain; serum IGF-I levels were unchanged. Serum IGFs in the lines containing the constructs 115 and 116 were not different from those of the controls. In all cases body length and weight as well as the weight of several organs such as brain, liver, kidneys, heart and spleen when expressed as a function of age did not differ from controls. Only the thymus showed a significant increase in weight in the transgenics II5′.
Inbreeding of 2 lines containing construct 115' with pituitary deficient Snell dwarf mice did not influence body length or weight despite increased serum IGF-II levels. Again the thymus showed a marked increase in growth. The biological activity of the IGF-II peptide was further demonstrated by increased serum IGF-binding protein-3 in the transgenic dwarf mice, as shown by Western ligand blotting.
In summary, overexpression of IGF-II in transgenic normal and dwarf mice does not affect overall body growth, but causes increased growth of the thymus. This suggests a role for IGF-II in thymic development by paracrine/autocrine action.
Journal of Endocrinology (1995) 144, 491–502
